Transparency Market Research (TMR) has published a new report titled, ‘Hemoglobin A1c Testing Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’. According to the report, the global Hemoglobin A1c Testing Devices market was valued at US$ 1,676.3 Mn in 2018 and is projected to expand at a CAGR of 10.7% from 2019 to 2027. Overview
Hemoglobin A1c testing devices are used to determine and monitor hemoglobin A1c levels in diabetic patients. For more than 500 million people affected with diabetes across the world, blood testing has become a routine part of managing the disease. A1C tests measure average blood glucose over the past two to three months. It is also known as glycosylated hemoglobin test, glycohemoglobin test, glycated hemoglobin test, or A1C. In terms of technology, ion-exchange HPLC segment dominated the market owing to the establishment of this technology as gold standard method of determination of HbA1c due to its excellent specificity and reproducibility. A clinical study by the company indicated that 205 patients with SC and diabetes were analyzed using immunoassay and HPLC instrument. The immunoassay study produced lower HBA1c compared to HPLC method. In terms of end-user, hemoglobin A1c testing devices are mostly used in laboratories and pointof-care units such as hospitals, clinics, home care, and others. North America dominated the global Hemoglobin A1c Testing Devices market in 2018 and the trend is anticipated to continue during the forecast period. High prevalence of different types of diabetes and rise in the geriatric population in the region are some of the factors augmenting the market in North America are expected to drive the market in North America. Asia Pacific is likely to be a highly lucrative market for retinal disorders and it is expected to expand at a high CAGR during the forecast period
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php? flag=B&rep_id=73900 Recent approval of HBA1C tests in year 2018 to Drive Market
A1CNow systems developed by PTS Diagnostics got approved in year 2018 which provides accurate A1C results in the office or home comes in a convenient 2-test pack or 4-test pack. Abbott laboratories got its Afinion assay product approved which is the first-ever rapid point-ofcare test approved to help diagnose diabetes and assess patients’ risk of developing the disease Bio-Rad Laboratories, Inc product VARIANT II System got its approval which offers fully automated high-volume hemoglobin A1c and β-thalassemia testing, with Clinical Data Management Software and a LIS interface.
Faster adoption and Increase in point-of-care testing to Drive Market
Point-of-care testing provides results within time limit, offers consumer convenience, reduces needle stick injuries, and minimizes contamination It has also led to development of the smaller devices, portable, and minimally invasive product. Hence, several laboratories are being converted into POC testing laboratories, as these can be